

Figure S1: Supplementary data to Figure 1. Real-Time PCR analysis of P_0 transcript illustrating P_0 invariance in response to LPS, TNFα, NaCl-hypertonicity and TGFα.

Figure 2

	TNFα	MCP-1	IκBα	AR	BGT1	SMIT
Ctl/SB203580	0.4±0.05	0.75±0.04	1.31±0.16	0.85±0.05	1.02±0.15	0.87±0.05
Ctl/Uo126	0.58±0.08	1.04±0.11	1.32±0.27	0.95±0.08	0.95±0.05	0.67±0.03
Ctl/SP600125	0.83±0.03	0.9±0.13	1.21±0.09	1.08±0.05	0.75±0.11	1.3±0.2
Ctl/c-Jun RNAi	1.2±0.1	0.98±0.15	1.15±0.15	-	-	-

Figure 5

	TNFα	MCP-1	IκBα
Ctl/MyD88 RNAi	0.55±0.18	0.95±0.07	0.77±0.05
Ctl/TNFR RNAi	0.92±0.31	0.88±0.21	0.91±0.16
Ctl/AG 1478	0.82±0.2	1.2±0.12	0.89±0.05

Figure 6

Ctl	TNFα	MCP-1	IκBα	AR	BGT1	SMIT
Ctl/AG 1478	0.82±0.2	1.2±0.12	0.89±0.05	1.13±0.32	2.99±0.13	1.05±0.3
Ctl/Wortmannin	2.05±0.34	1.26±0.14	1.0±0.04	1.2±0.21	1.14±0.16	1.34±0.27
Ctl/Triciribine	0.56±0.06	1.68±0.3	1.21±0.12	0.54±0.02	0.55±0.19	0.56±0.1
Ctl/SB203580	0.47±0.15	0.8±0.1	1.2±0.12	0.69±0.04	0.71±0.19	0.55±0.05

Figure S2: Supplementary data to Figures 2, 5 and 6. Real-Time PCR analysis illustrating the effects of pharmacological inhibitors and RNAi on basal mRNA expression of investigated genes.



Figure S3: Supplementary data to Figure 2. (**A**) Comparison of the effects of 10 μM SB203580 and 10 μM U0126 on TNFα, MCP-1 and IκBα mRNA expression levels in cells challenged with LPS, TNFα or hypertonc medium (NaCl). Data is represented as fold decrease of inducible mRNA expression by pharmacological inhibitors. The ratio of mRNA transcripts in the presence and absence of each inhibitor is shown at far right. Notice the absence of an effect by SB203580 on IκBα mRNA induction by hypertonicity. (**B** and **C**) Comparison of the effects of 10 μM SP600125 (**B**) and RNAi against c-Jun (**C**) on TNFα, MCP-1 and IκBα mRNA expression levels. Data is represented as fold decrease of inducible mRNA expression by pharmacological inhibitors or RNAi. The ratio of mRNA transcripts in the presence and absence SP600125 or RNAi is shown in (**D**).



Figure S4: Supplementary data to Figure 5. (**A**) Comparison of the effects of LPS, TNFα, TGFα or hypertonic medium (NaCl) applied alone or in pairs on TNFα, MCP-1 and IκBα mRNA expression levels. Data is represented as fold expression over cells challenged with LPS, TNFα, or hypertonicity alone. The insert shows the effects of TGFα (100 ng/ml) on mRNA expression. Notice the absence of an effect by TGFα on IκBα mRNA expression. (**B**) Comparison of the effects of RNAi against MyD88, RNAi against both TNFR1 and TNFR2 and 10 μM of the EGFR antagonist AG1478 on TNFα, MCP-1 and IκBα mRNA expression in cells challenged with LPS, TNFα, TGFα or hypertonic medium. Data is represented as fold expression over cells challenged with either stimulus alone. Notice the absence of an inhibitory effect by AG1478 on IκBα mRNA expression.



Figure S5: Supplementary data to Figure 6. (**A** and **B**) Comparison of the effects of 100 nM wortmannin, 30 μM triciribine (**A**) or 10 μM SB203580 and 30 μM triciribine applied alone or together (**B**) on hypertonic stimulation (NaCl) of TNFα, MCP-1 and IκBα mRNA expression. Data is represented as the ratio of transcript expression induced by hypertonic challenge in the presence and absence of pharmacological inhibitors. Notice the absence of an inhibitory effect by any pharmacological compound on hypertonicity-induced IκBα mRNA expression.